Lignocaine kinetics in cardiac patients and aged subjects.

1 The pharmacokinetics following long term intravenous infusion of lignocaine to cardiac patients have been examined. 2 Plasma levels and half-lives of lignocaine and monoethylglycinexylidide (MEGX) showed wide inter-patient variability. 3 Toxicity reactions to therapy were associated with elevated lignocaine and/or MEGX plasma levels. 4 In a separate study the effect of age on the pharmacokinetics of lignocaine was examined using bolus doses (50 mg) of the drug to young and aged subjects. 5 Elderly subjects had significantly longer half-lives for lignocaine compared to younger individuals although no change in plasma clearance occurred. 6 The drug appeared to distribute differently in the aged as reflected by significantly increased apparent volumes of distribution. 7 The 24 h urinary recovery of the major metabolite (total 4-hydroxyxylidine) showed a significant reduction in the elderly when compared to the young. 8 The clinical significance of these studies with respect to lignocaine therapy has been discussed.

[1]  L. Prescott,et al.  Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure. , 1976, British medical journal.

[2]  John G. Wagner,et al.  Model-Independent Linear Pharmacokinetics , 1976 .

[3]  R. Nation,et al.  Gas chromatographic method for the quantitative determination of lidocaine and its metabolite monoethylglycinexylidide in plasma. , 1976, Journal of chromatography.

[4]  P. Poole‐Wilson,et al.  Logical approach to lignocaine therapy. , 1976, British medical journal.

[5]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[6]  P. Meffin,et al.  Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite , 1975, Clinical pharmacology and therapeutics.

[7]  U. Klotz,et al.  The effects of age and liver disease on the disposition and elimination of diazepam in adult man. , 1975, The Journal of clinical investigation.

[8]  R. Burney,et al.  Anti-arrhythmic effects of lidocaine metabolites. , 1974, American heart journal.

[9]  J. Strong,et al.  The convulsant potency of lidocaine and its N-dealkylated metabolites. , 1973, The Journal of pharmacology and experimental therapeutics.

[10]  W. Steinbrunn,et al.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. , 1973, Annals of internal medicine.

[11]  A. Atkinson,et al.  Identification of glycinexylidide in patients treated with intravenous lidocaine , 1973, Clinical pharmacology and therapeutics.

[12]  A. Atkinson,et al.  Simultaneous measurement of plasma concentratons of lidocaine and its deethylated metabolite by mass fragmentography , 1972 .

[13]  K. Melmon,et al.  The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man. , 1971, American heart journal.

[14]  D. Scott,et al.  Pharmacokinetics of lidocaine in man , 1971, Clinical pharmacology and therapeutics.

[15]  D C Harrison,et al.  Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. , 1967, The New England journal of medicine.

[16]  A. Beckett,et al.  The metabolism and excretion of lignocaine in man , 1966 .

[17]  N. Shock,et al.  Changes in Cardiac Output with Age , 1955, Circulation.

[18]  B. Billing,et al.  Splanchnic blood flow in man by the bromsulfalein method: the relation of peripheral plasma bromsulfalein level to the calculated flow. , 1950, The Journal of laboratory and clinical medicine.

[19]  D F DAVIES,et al.  Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. , 1950, The Journal of clinical investigation.

[20]  D. Morgan,et al.  Metabolism of etidocaine in man. , 1976, Xenobiotica; the fate of foreign compounds in biological systems.